Globe Biotech allowed to produce ‘Bangavax’ vaccine for trial
Published: 01:39 PM, 6 January 2021 Updated: 03:42 PM, 6 January 2021
Bangladeshi company Globe Biotech got approval to produce 'Bangavax', the Covid-19 vaccine for clinical trials. The trial is likely to begin from this month.
Earlier, the pharmaceutical company's coronavirus vaccine was named 'Bancovid'. Following a proposal of Secretary of Ministry of Health and Family Welfare Abdul Mannan, Chairman of Globe Biotech Harunur Rashid changed the name of the vaccine to “Bangavax”.
Later, Director General of Directorate General of Health Services (DGHS) ABM Khurshid Alam praised the name saying that the name would represent Bangla and Bangabandhu as well, so it would be a good name.
Earlier on July 3 last year, claiming success in preliminary animal modelling trial for Covid-19 vaccine, Globe Biotech Limited has claimed to be the first company from Bangladesh to have a Covid-19 vaccine under development.
Later on October 10, the company announced that they have gotten encouraging results from pre-clinical trials, initially done on rabbits and then mice. The pre-clinical trial results were pre-published in the international platform, biorxive.org - an archive for unpublished pre-prints in life sciences.